Breast Cancer Coverage from Every Angle
Advertisement
Advertisement

Massimo Cristofanilli, MD, on Clinical Implications of Treatment With Palbociclib Plus Fulvestrant for Breast Cancer

Posted: Monday, June 7, 2021

Massimo Cristofanilli, MD, of the Feinberg School of Medicine at Northwestern University, talks about why the phase III PALOMA-3 trial provides key evidence for clinicians prescribing palbociclib plus fulvestrant for women with advanced hormone receptor–positive, HER2-negative breast cancer. He also addresses toxicities associated with this combination and how to manage them.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.